Protiva Biotherapeutics (Burnaby, BC)

CMDF Investment: $5,750,000.00
Focus: Cancer   Inflammatory Diseases  
www.protivabio.com

Protiva is a biotechnology company developing a systemic; non-viral gene-delivery platform. Protiva was spun out of Inex Pharmaceuticals Corporation in 2001; where the technology had been under preclinical development for six years. Protiva is focused on becoming a leader in targeted; gene-delivered protein products that are safe and effective for use in the treatment of cancer and inflammatory diseases.